Widely used diabetes drug may offer unexpected health benefit

Key Points:

• New research from Stanford University indicates that adults with type 2 diabetes taking metformin before contracting COVID-19 had a 39% lower risk of death within a year compared to those on other diabetes medications.
• The study, published in Diabetes, Obesity and Metabolism, suggests metformin may offer protective effects beyond blood sugar control, potentially influencing biological pathways related to COVID-19 severity.
• Analysis of over 53,000 U.S. medical records showed metformin users, who were generally younger and healthier, had better survival rates than those on dipeptidyl peptidase-4 inhibitors (DPP4i), though the study cannot confirm causation.
• While initial data hinted at reduced long COVID symptoms among metformin users, further testing found no significant link, and experts emphasize that these findings do not warrant changes in diabetes treatment without more evidence.
• Researchers and clinicians caution that differences in patient health and incomplete vaccination data limit conclusions, and patients should not alter their prescribed medications based on this study alone.